Due to the DNA repair defects in FA, patients with the disease have an extremely high risk of developing cancer. The most common solid tumors diagnosed in the FA population are squamous cell cancers of the head and neck and anogenital regions, although tumors can occur in other areas as well. The age of onset is often younger in FA patients compared to the general population and the risk is increased in patients who have undergone hematopoietic stem cell transplantation. Treating cancer in individuals with FA is difficult as many therapies used for the general public are contraindicated due to issues related to toxicity.

**THE PROBLEM**

**CANCER IN PEOPLE WITH FANCONI ANEMIA (FA)**

Due to the DNA repair defects in FA, patients with the disease have an extremely high risk of developing cancer. The most common solid tumors diagnosed in the FA population are squamous cell cancers of the head and neck and anogenital regions, although tumors can occur in other areas as well. The age of onset is often younger in FA patients compared to the general population and the risk is increased in patients who have undergone hematopoietic stem cell transplantation. Treating cancer in individuals with FA is difficult as many therapies used for the general public are contraindicated due to issues related to toxicity.

**A SOLUTION**

**THE FCF VIRTUAL TUMOR BOARD, A TEAM OF EXPERTS WHO OFFER GUIDANCE ON TREATING FA-RELATED CANCER**

The Fanconi Cancer Foundation (FCF) Virtual Tumor Board (VTB) is a panel of physicians experienced with treating patients with FA. The physicians volunteer their time to discuss difficult FA solid tumor and hematologic cases and offer treatment guidance. The specialists on the panel have expertise in otolaryngology, hematology oncology, radiation oncology, and medical oncology.

The VTB was developed to provide support to individuals with FA and their treating physicians. Members of the FCF VTB will meet virtually with the patient’s local treating physician(s) to review a patient’s case and provide input for treatment, from an FA-centric viewpoint. This process allows continued learning on how to best treat cancers associated with FA, which in turn may help others with similar diagnoses.

**HOW TO PARTICIPATE**

Please send a brief synopsis of the patient’s cancer-related medical history, along with the timeframe in which you would like the VTB to occur, to Andrea Ronan: andrea@fanconi.org or 541-687-4658 ext 302. We will provide you with more details on the process and coordinate the meeting with the VTB members.
The Fanconi Cancer Foundation (FCF) Virtual Tumor Board (VTB) is a panel of physicians, experienced and knowledgeable in Fanconi anemia (FA), who volunteer their time to meet, as needed, to discuss difficult FA solid tumor and hematologic cases and offer treatment guidance.

A RESOURCE FOR PHYSICIANS WITH FA PATIENTS DIAGNOSED WITH CANCER

The Fanconi Cancer Foundation (FCF) Virtual Tumor Board (VTB) is a panel of physicians, experienced and knowledgeable in Fanconi anemia (FA), who volunteer their time to meet, as needed, to discuss difficult FA solid tumor and hematologic cases and offer treatment guidance.

THE VIRTUAL TUMOR BOARD PROCESS

- The VTB will meet via Zoom; a password protected link will be sent with your meeting invite.
- You will open the VTB meeting by presenting the case and sharing any pertinent patient records.
- The VTB meeting will last 15-20 minutes to be mindful of participants schedules.
- Meetings will be recorded.

PREPARATION

All pertinent patient imaging, records or pathology reports should be readily accessible for you to share during the VTB meeting via screen share on Zoom.

FOLLOW-UP

An FCF staff member will follow up with you 1-2 weeks after the VTB for feedback on the VTB process and 2-4 weeks after treatment to monitor the patient’s response to treatment.

Please reach out to FCF staff (Andrea Ronan at andrea@fanconi.org) with any further questions, concerns, or treatment changes at any time following the VTB. Subsequent meetings can be scheduled as needed.

ABOUT THE FANCONI CANCER FOUNDATION

Our mission is to improve the lives of people affected by Fanconi anemia and associated cancers worldwide by funding exceptional research and empowering our community.

Founded in 1989 by parents Lynn and David Frohnmayer, FCF’s contributions have been instrumental in understanding the disease and improving treatments, with more than $33 million funded for 260+ research projects worldwide. Life expectancy has more than doubled as treatments have drastically improved. We must now take on the most significant and currently unsolved problem facing the FA community today: cancer.